Minnuo Biotechnology

Minnuo Biotechnology is a clinical-stage Chinese biotechnology company specialized in the development of next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of solid tumors. The company focuses on overcoming the immunosuppressive challenges of the tumor microenvironment to improve the infiltration and persistence of immune cells within solid cancers. Its lead candidate, MN-101, is a Claudin 18.2-targeted CAR-T therapy currently undergoing Phase 1 clinical evaluation for patients with advanced gastric and pancreatic cancers. Headquartered in Hangzhou, Minnuo Biotechnology leverages its proprietary technology platforms to advance a robust pipeline of engineered cell therapies targeting validated antigens such as Mesothelin.